Adil Al Hasan, Jakarta – PT Kimia Farma Tbk posted a current-year loss of Rp234.1 billion from January to September 2025. This figure is down from Rp550.8 billion in the same period last year.

According to its financial report on the Indonesia Stock Exchange, the company, codenamed KAEF, generated net sales of Rp7 trillion, down from Rp7.8 trillion in the same period last year.

KAEF's revenue comes from both domestic and international sales. Domestically, KAEF generated Rp6.3 trillion in sales from third parties and Rp521.2 billion from related parties. Meanwhile, international sales consisted of Rp125.1 billion in sales of quinine salts and essential oils, and Rp1.7 billion in sales of medicines and medical devices.

KAEF's cost of goods sold decreased from Rp5.5 trillion in September 2024 to Rp4.5 trillion by September 2025. KAEF's gross profit was recorded at Rp2.4 trillion, an increase from Rp2.3 trillion in the same period last year.

As of September 30, 2025, KAEF had total liabilities of Rp11.7 trillion and equity of Rp3.1 trillion. KAEF's total assets were recorded at Rp581.5 trillion, a decrease from Rp618 trillion in December 2024.

This year, Kimia Farma also plans to sell 38 assets worth Rp2.1 trillion. The assets sold include a building in Cikarang, West Java, worth Rp347 billion and 37 others worth Rp1.8 trillion.

In a disclosure to the Indonesia Stock Exchange on Thursday, October 30, 2025, KAEF management stated that the asset transfer involved one transaction from an affiliate, PT Bio Farma, which acquired assets in Cikarang.

The remaining assets will be transferred through a public offering or auction through the State Assets and Auction Service Office (KPKNL). If the auction is unsuccessful, management will pursue a limited offering or direct appointment.

Management stated that the Rp347 billion proceeds from the sale of the Cikarang assets will be used to settle trade payables and repay debt, meet regulatory payment requirements, and meet core operational needs that directly impact production and sales.

Meanwhile, proceeds from the sale of 37 assets worth Rp1.8 trillion will be used 50 percent for mandatory prepayment obligations for the Tranche B financing facility and 50 percent for working capital, debt repayment, and other needs.

Source: https://en.tempo.co/read/2062813/kimia-farma-loses-rp234-billion-in-the-third-quarter-of-202